c.) Amendments to the Claims

Claim 1. (Cancelled)

2. (Currently Amended) A compound according to claim 1, represented by formula (I):

$$R^1-A-R^2 \qquad (I)$$

wherein

<u>(Ic):</u>

R¹ represents substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl or a hydrogen atom;

R² represents hydroxy, substituted or unsubstituted alkoxy, or substituted or unsubstituted amino; and

A is represented by the general formula (Ia); formulae (Ia), Ib) or

-
$$(X^{1})n$$
 - $(X^{2})n$ - $(X^{3})n$ - $(Ala)n$ - $(X^{5})n$ - $(X^{6})n$ - $(X^{7})n$ - $(X^{8})n$ - $(X^{9})n$ - Val -

(wherein "n's" in individual amino acid residues are the same or different, and independently represent 0 or 1; X^1 , X^8 , \dot{X}^{27} and X^{28} are the same or different, independently represent Leu or Ile; X^2 represents Asn or Lys; X^3 represents Trp, Lys, Leu,

Ala or Glu; X^5 represents Ala or Ser; X^6 represents Glu, Asp or Asn; X^7 represents Val, Thr or Arg; X^9 represents Lys, Asp, Ala or His; X^{26} represents Gln, His, Gly, Asp or Asn; and X^{29} represents Ala, Arg, Lys or Glu), or by the general formula (Ib);

$$-(Y^{1})m$$
 $-(Y^{2})m$ $-(Y^{3})m$ $-(Gln)m$ $-(Y^{5})m$ $-(Y^{6})m$ $-(Asp)m$ $-(Gln)m$ $-(Y^{9})m$ $-(Asn)m$ $-(Asn)m$ $-(Y^{6})m$ $-(Asp)m$ $-(Asp)m$

(wherein "m's" in individual amino acid residues are the same or different, and independently represent 0 or 1; Y¹ represents Asn, Thr, Ala or Tyr; Y² represents Glu or Asp; Y³ represents Ser or Asn; Y⁵ represents Ala or Asn; Y⁶ represents Tyr or Cys; Y⁰ represents Lys or Glu; Y²⁵ represents Met or Ile; and Y²ⁿ represents Ile or Val), or by the general formula (Ic);

-
$$(Z^{1})p$$
 - $(Z^{2})p$ - $(Z^{3})p$ - $(Z^{4})p$ - $(Z^{5})p$ - $(Z^{6})p$ - $(Z^{7})p$ - $(Z^{8})p$ - $(Z^{9})p$ - $(Z^{10})p$ - $(Z^{11})p$ - $(Z^{12})p$ - $(Z^{13})p$ - $(Z^{14})p$ - $(Z^{15})p$ - $(Z^{15})p$ - $(Z^{16})p$ - $(Z^{17})p$ - $(Z^{18})p$ - $(Z^{19})p$ - $(Z^{20})p$ - $(Z^{21})p$ - $(Z^{22})p$ - $(Z^{23})p$ - $(Z^{24})p$ - $(Z^{25})p$ - Arg - Z^{27} - Z^{28} - Z^{29} - Ser - Leu - Z^{32} - Leu - Z^{34} - Thr - Z^{36} - Z^{37} - Phe - Z^{39} - Z^{40} - Leu -

(Ic, SEQ ID NO:27)

(wherein "p's" in individual amino acid residues are the same or different, and independently represent 0 or 1; Z¹ represents Ala, Phe or Pro; Z² represents Arg, Lys, or

Gln; Z^3 , Z^{15} and Z^{21} are the same or different, representing independently represent Gly or Pro; Z^4 represents Arg, Lys, Met or Pro; Z^5 represents Gly, Cys, Ala or Gln; Z^6 represents Ala, Arg or Glu; Z^7 represents Ala, Ile or Gln; Z^8 represents Ala, Gly or Arg, Z^9 represents Leu, Val or Pro; Z^{10} represents Asp, Arg or Gln; Z^{11} represents Gly, Ser, Ala or Pro; Z^{12} represents Leu or Pro; Z^{13} represents Asp, His or Pro; Z^{14} represents Ser or Pro; Z^{16} represents Gln or Lys; Z^{17} represents Gly, Thr or Leu; Z^{18} represents Gly, Pro or Val; Z^{19} represents Gly or Lys; Z^{20} represents Ala or Ser; Z^{22} represents Gly or Ser; Z^{23} represents Gly, Glu or Thr; Z^{24} represents Arg, Lys, Ser or Pro; Z^{25} represents Ser or Thr; Z^{27} represents His or Tyr; Z^{28} represents Asp or Glu; Z^{29} and Z^{36} are the same or different, representing independently represent Lys or Thr; Z^{32} represents Gly or Asn; Z^{34} represents Leu or Thr; Z^{37} represents Arg or Lys; Z^{39} represents Ile, Leu or Val; and Z^{40} represents Glu, Gln, Ser or Tyr);

or a pharmaceutically acceptable salt thereof

with the proviso that A is not an intact peptide that which is a

member of E2F family or DP family.

3. (Currently Amended) A pharmaceutical composition comprising:

a pharmaceutically pure compound represented by the general formula (I);:

$$R^1-A-R^2 \qquad (I)$$

(wherein

R¹ represents substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl or a hydrogen atom;

R² represents hydroxy, substituted or unsubstituted alkoxy, or substituted or unsubstituted amino; and

A represents a peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the dimerization region or DNA binding region of each E2F family)

or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

- 4. (New) A compound according to claim 2, wherein A comprises SEQ ID NO:25, or a pharmaceutically acceptable salt thereof.
- 5. (New) A compound according to claim 2, wherein A consists of SEQ ID NO:26, or a pharmaceutically acceptable salt thereof.
- 6. (New) A compound according to claim 2, wherein A consists of SEQ ID NO:27, or a pharmaceutically acceptable salt thereof.
 - 7. (New) A compound according to claim 6, wherein A consists of:

```
- Ile - Arg - Arg - Arg - Val -
Tyr - Asp - Ala - Leu - Asn -
Val - Leu - Met - Ala - Met -

(SEQ ID NO:23)
```

or a pharmaceutically acceptable salt thereof.

8. (New) A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to claim 7, and a pharmaceutically acceptable carrier.